ABBV

Generated on 30/03/2026 | Market: NYSE | Status: PRE-MARKET

AbbVie Inc. is one of the leading global biopharmaceutical companies, focused on the development of innovative therapies in immunology, oncology, neuroscience and medical aesthetics through the Allergan portfolio (Botox). The current growth engine is the Skyrizi/Rinvoq pair, which has more than offset the erosion of the Humira franchise following patent expiry. The company operates primarily in the United States and is listed on the NYSE. GICS classification: Health Care — Pharmaceuticals.

ABSENT

AI Disruption Risk: LOW. Artificial intelligence acts as an accelerator in drug discovery and clinical trial optimization processes, without threatening the business model based on patents, clinical efficacy and regulatory barriers.

B1.1 — Leadership and systemic role: 8.75

AbbVie holds a structural leadership position in global immunology, with Skyrizi and Rinvoq growing rapidly and expanding market shares in psoriasis, rheumatoid arthritis and frontline IBD. The medical aesthetics franchise (Botox) maintains uncontested leadership in the segment. The post-Humira transition has proven more effective than any historical precedent in the pharmaceutical sector, confirming the company’s ability to regenerate its commercial portfolio. It does not reach the level of an absolute monopoly because credible competitors (J&J, Pfizer) are present in some therapeutic indications.

B1.2 — Customers and barriers to entry: 8.50

Barriers to entry are structurally high: multi-year patent protection, FDA/EMA regulatory complexity, significant clinical switching costs for patients on chronic biologic therapy, and a consolidated network with specialist prescribers and payers. The focus on biologics — molecules that are difficult to replicate faithfully with biosimilars — adds a further layer of competitive protection compared with small-molecule drugs.

B1.3 — Business economics: 8.25

The economic quality of the business is high: gross margin ~70%, adjusted operating margin ~35-38%, historical ROIC 15-20%. 2025 operating cash flow reached $19.03B, with free cash flow of $17.82B. The reported earnings profile is temporarily noisy due to IPR&D charges, amortization of acquired intangibles and extraordinary items linked to acquisitions, but the structural cash generation capacity is solid and verifiable.

B1.4 — Balance sheet and resilience: 6.50

This is the relative weak point of AbbVie’s profile. Long-term debt amounts to $64.50B, total liabilities ($137.19B) exceed total assets ($133.96B), with negative book equity of $3.23B — a consequence of the Allergan acquisition and other transformative deals. Interest Coverage of 3.19x and an Altman Z-Score of 2.44 indicate acceptable but not comfortable solvency. Resilience is supported by robust cash generation and a manageable debt maturity profile; the deleveraging path is ongoing but requires monitoring.

B2.1 — Sector cycle: 6.75

The pharmaceutical sector is in a decent but not euphoric phase: final demand is solid and structurally inelastic, earnings estimate revisions are predominantly positive, and the aggregate revenue trend is expanding, driven by therapeutic innovation. These positives are counterbalanced by the sector patent cliff and regulatory pressure on prices — particularly the Inflation Reduction Act in the United States — which represent structural headwinds with measurable impact on future margins. The balance between positive and negative factors is favorable but not overwhelming.

B2.2 — Structural trends: 8.00

The medium- to long-term context is strongly supportive. Global demographic aging, the increasing prevalence of autoimmune and oncological diseases, and the expansion of the medical aesthetics market constitute clear and quantifiable secular drivers. IQVIA forecasts growth in global pharmaceutical spending through 2030, with immunology, oncology and neuroscience as central axes — exactly AbbVie’s areas of excellence.

B2.3 — Competitive positioning in the cycle: 8.00

AbbVie outperforms the sector average in the current phase across multiple dimensions: high double-digit Skyrizi/Rinvoq revenue growth, 2026 guidance at ~$67B (vs $61.16B in 2025), low beta (0.33-0.44) and margin resilience above peers. The demonstrated ability to navigate the loss of exclusivity of the world’s best-selling drug without a material contraction in earnings places AbbVie in the high end of the sector for operating execution in the current cycle.

B2.4 — Exogenous risks: 6.00

External risks are concrete and priced by the market. Regulatory pressure on prices in the United States (Medicare negotiation through the IRA) represents the main risk, with potential impact on long-term margins. Added risks include residual biosimilar competition on Humira, geopolitical risk on the supply chain (India/China), and the potential need for strategic M&A to maintain the pipeline growth pace beyond 2030. The score reflects tangible risks that are already partly incorporated in market pricing.

B3.1 — Intrinsic Fair Value: 6.00

Weighted Fair Value: $233.20 — 4 sources out of 4 available (ValueInvesting $128.23, GuruFocus $199.36, Alpha Spread $233.88, Simply Wall St $371.32). The current price of $209.40 implies an 11.1% discount to weighted fair value, placing the stock in the “Slight discount” range (base score 6.50). Dispersion among models is extreme: 116.1% of the price, with MIXED type (ValueInvesting and GuruFocus indicate overvaluation, Alpha Spread and Simply Wall St indicate undervaluation). MIXED dispersion penalty >60%: −0.50. Final score: 6.00. The exceptional dispersion reflects structural uncertainty in DCF models applied to a company with distorted EPS TTM and large acquired intangibles. Business Score = 8.00 (not strictly >8.00): Excellence Premium not applicable.

B3.2 — Analyst consensus: 7.34

Consensus_Score: (22/33 × 10) − 0 = 6.67. Upside_Score: +20–29.99% range = 8.00. B3.2 = (6.67 + 8.00) / 2 = 7.34. Consensus is positively oriented with an average target implying upside above 20% versus the current price. The “buy now” component (19 out of 33) is dominant, with a total absence of sell recommendations. Source: TradingView (33 analysts, 3-month window, 30/03/2026).

B3.3 — Relative valuation: 2.00

The P/E TTM of 88.69x — while distorted by a one-off extraordinary loss of ~$5B in 2025 — does not satisfy the required AND condition: the multiple is significantly above both the company’s 5-year historical average (~50x) and the sector average (~24x). The gap versus peers is extreme (+269%) and the gap versus historical is very wide (+77%), making both dimensions markedly unfavorable. On an adjusted basis (EPS ~$10.12, normalized P/E ~20x), the picture would be radically different, but the framework applies the reported TTM metric. The score reflects the reality of published multiples, not the underlying business quality.

B3.4 — FCF & Net Shareholder Yield: 9.00

FCF TTM: $17.82B (2025 Operating Cash Flow $19.03B − Capex $1.21B, source: SEC 10-K). Market Cap: $370.38B. FCF Yield: 4.81%. Dividend Yield: 3.30% (annual dividend ~$12.22B). Net Share Issuance: ~0%. Net Shareholder Yield: 8.11% — 8.0–9.99% range, score 9.00. Implied shareholder remuneration is high and solidly covered by operating cash generation. Capex/OCF = 6.4%: no condition for conventional score. Metric used: Net SY.

Combined profile: Solid business, positive outlook, fair valuation.

Competitive Advantage and Moat

AbbVie’s competitive moat is based on patents, global commercial scale and clinical switching costs. The moat is currently stable with signs of expansion: Skyrizi/Rinvoq is building a new exclusivity base in adjacent segments (subcutaneous IBD label expansion, new dermatological indications), while the neuroscience portfolio and oncology pipeline offer potential structural diversification beyond 2028. The strongest demonstration of the moat’s value is the management of Humira’s patent cliff — the world’s best-selling drug for more than a decade — executed with minimal overall revenue loss thanks to the accelerated ramp of successors.

General Cycle and Competitive Dynamics

The pharmaceutical sector is going through an active consolidation phase, with accelerating M&A and capital returning toward assets with credible pipelines. AbbVie is gaining market share in immunology versus its main competitors, with pricing power confirmed on next-generation biologic therapies. Biosimilar pressure on Humira is now largely absorbed and no longer represents a relevant incremental risk for the aggregate financial profile.

Catalysts and Future Opportunities (Bull Case)

The combined growth of Skyrizi and Rinvoq is expected to exceed $31B in 2026, with further expansion in recently approved new subcutaneous IBD indications. The neuroscience pipeline (Parkinson’s treatment with estimated potential peak sales >$5B) represents the main medium-term catalyst. 2026 guidance at ~$67B in revenue and adjusted EPS of $14.37-$14.57 implies double-digit growth with stable margins. Dividend yield above 3%, covered by robust FCF, offers a stable return while waiting for the neuroscience and oncology pipeline to mature toward approval.

Risks (Bear Case)

The main risk is regulatory pressure on U.S. prices through the IRA Medicare negotiation mechanism, with potential structural impact on long-term margins. Additional risks include pipeline risk on phase 3 studies in neuroscience and oncology (sectors with high outcome variability), residual financial leverage that limits flexibility for transformative acquisitions without impact on the credit rating, and the possibility that biosimilar competition in immunology becomes more aggressive than expected in the leading indications of Skyrizi/Rinvoq after 2030.

Solid business, fair valuation. Limited opportunity at the current price. NEUTRAL.

Why it could be an opportunity

The market has shown that it underestimated the speed and quality of the post-Humira transition. Skyrizi and Rinvoq are growing at rates without historical precedent for a company that lost exclusivity on the world’s best-selling drug. The weighted fair value ($233.20) implies 11% upside versus the current price, and analyst consensus indicates potential of +22%. The 8.1% Net Shareholder Yield offers solid implied remuneration for medium- to long-term investors, while waiting for the neuroscience and oncology pipeline to mature toward approval.

Why it could be a risk

Dispersion among fair value models is among the highest in the large-cap biopharmaceutical universe (116% of the price), with sources diverging on the very direction of over/undervaluation. The P/E TTM of 88.69x — while distorted — makes the stock expensive versus any sector multiple reference, limiting multiple expansion as a return driver. Residual financial leverage, in a context of still-elevated rates, compresses operating flexibility for inorganic growth.

Price Target Table

This analysis is produced by the Score³ system for informational purposes only and does not constitute financial advice, a solicitation to invest, or a trading or investment recommendation. Data is collected from public sources and may contain errors or delays. Fair value estimates and price targets are model-based projections subject to significant uncertainty and do not represent certain forecasts. Investing involves risks, including the possible loss of invested capital. Always verify critical data against primary sources before making any investment decision. Past performance is not indicative of future results.